Photo by mykjohnson from unsplash
To evaluate the immunogenicity of LY2963016 insulin glargine (LY IGlar) versus originator insulin glargine (IGlar [Lantus®]) in Chinese patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM). Click to show full abstract
To evaluate the immunogenicity of LY2963016 insulin glargine (LY IGlar) versus originator insulin glargine (IGlar [Lantus®]) in Chinese patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM).
Keywords:
chinese patients;
insulin;
immunogenicity ly2963016;
insulin glargine;
ly2963016 insulin
Journal Title: Diabetes
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!